ClinicalTrials.gg
CompletedNCT01308580PROSELICAUpdated Apr 17, 2017Results posted

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

A Phase 3 interventional study of Cabazitaxel (XRP6258) and Prednisone (or Prednisolone) in Prostate Cancer, sponsored by Sanofi. Completed at 172 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
Largest of 46
1,200 · median 60
Started
2011
with 4 others
Phase 3
7 of 46
none open now
Registered
3rd of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one has the largest enrollment, is one of 5 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.

Secondary Objectives:

  • To evaluate safety in the 2 treatment arms and to assess if Cabazitaxel 20 mg/m² was better tolerated than Cabazitaxel 25 mg/m².
  • To compare efficacy of Cabazitaxel at 20 mg/m² and 25 mg/m² for:

    • Progression Free Survival (PFS) defined as the first occurrence of any of the following events: tumor progression per Response Evaluation Criteria In Solid Tumors (RECIST), prostate-specific antigen (PSA) progression, pain progression or death due to any cause;
    • PSA Progression;
    • Pain progression;
    • Tumor response in participants with measurable disease (RECIST 1.1);
    • PSA response;
    • Pain response in participants with stable pain at baseline.
  • To compare Health-related Quality of Life (HRQoL).
  • To assess the pharmacokinetics and pharmacogenomics of Cabazitaxel.
Read the detailed description

Participants were treated until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles. All participants were followed when on study treatment and after completion of study treatment during follow up period until death or the study cutoff date, whichever came first.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I 01. Diagnosis of or cytologically proven prostate adenocarcinoma, that was resistant to hormone therapy and previously treated with a docetaxel-containing regimen.

I 02. Participant must had either measurable or non-. I 03. Received prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH) agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other hormonal agents.

I 04. > 6 months. I 05. (ECOG) performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all self-care, and up and about more than 50% of waking hours).

I 06. Age ≥18 years (or country's legal age of majority if the legal age was > 18 years).

Exclusion criteria

Exclusion criteria:

E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or radiotherapy to ≥30% of bone marrow. In case of prior isotope therapy 12 weeks must had elapsed prior to first study drug administration.

E 03. Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria [] v4.03) at the time of randomization.

E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study.

E 05. Prior . Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which chemotherapy had been completed ≥ 5 years ago and from which the participant had been disease-free for ≥ 5 years.

E 06. Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization.

E 07. Known brain or . E 08. Other concurrent serious illness or medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure ( III or IV) or myocardial infarction within last 6 months was also not allowed.

E 10. Any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or to comply with the study procedures or interfere with interpretation of study results.

E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant form prior to enrollment into the study.

E 12. Participants with who did not agree to use accepted and effective method of during the study treatment period. The definition of "effective method of contraception" was based on the Investigator's judgment. Participant's Partners of (unless surgically sterile, post menopausal or for another reason had no chance of becoming pregnant) not protected by highly effective contraceptive method of birth control as defined for contraception in the Informed Consent Form and /or in a local protocol addendum.

E 13. History of to docetaxel, or polysorbate 80. E 14. Inadequate organ and bone marrow function. E 15. to the use of treatment. E 16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (actual)

Study arms

  • Experimental
    Cabazitaxel 20 mg/m^2

    Cabazitaxel 20 mg/m\^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.

    Drug: Cabazitaxel (XRP6258) · Drug: Prednisone (or Prednisolone)

  • Experimental
    Cabazitaxel 25 mg/m^2

    Cabazitaxel 25 mg/m\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.

    Drug: Cabazitaxel (XRP6258) · Drug: Prednisone (or Prednisolone)

Interventions

  • Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous

    Also known as: Jevtana®

  • Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive or the study cut-off date. The cut-off date for the final analysis of OS was the date when the 988th death had been observed. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was evaluated from date of randomization to date of first documentation of any of the events: 1) Radiological tumor progression: as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target lesions, 2) Prostate Specific Antigen (PSA) progression: ≥25% increase over baseline/nadir value if baseline PSA ≥10 ng/mL; or 25% increase above the baseline level if baseline PSA \>0 ng/mL \& \<10 ng/mL; or post-baseline value of \>=2 ng/mL, if baseline PSA=0 ng/mL, 3) Pain progression: increase of ≥1 point in median Present Pain Intensity (PPI) from nadir or ≥25% increase in mean analgesic score (AS) from baseline score or requirement of local palliative radiotherapy, 4) Death. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline up to tumor progression, PSA progression, pain progression, death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

  2. Time to Tumor Progression

    Time to Tumor progression was defined as the first occurrence of radiological tumor progression according to RECIST 1.1. Radiological tumor progression was defined at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target-lesions. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

  3. Percentage of Participants With Overall Objective Tumor Response

    Overall objective tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1 criteria, as assessed by the investigator. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

  4. Time to PSA Progression

    Time to PSA progression was time interval between randomization \& first occurrence of PSA progression. PSA progression defined as: 1) PSA responders (\>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over nadir value, confirmed by second PSA ≥3 weeks later; 2) PSA non-responders (did not achieve \>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over baseline value, confirmed by second PSA ≥3 weeks later; 3) In participants not eligible for PSA response (baseline PSA \<10 ng/mL): (a) participants with baseline PSA \>0 ng/mL \& \<10 ng/mL: increase in PSA by 25% (≥2 ng/mL) above baseline level, confirmed by second PSA value ≥3 weeks apart; (b) participants with baseline value=0 ng/mL: post-baseline PSA value ≥2 ng/mL. Note (for 1-3): Rise in PSA in first 12 weeks was progression only if met definition above and was associated with other sign of DP or if it continued beyond 12 weeks. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

  5. Percentage of Participants With PSA Response

    PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.

    Time frame: From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

  6. Time to Pain Progression

    Pain Progression was defined as an increase of ≥1 point in the median PPI from its nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean AS compared with the baseline score confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. AS was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)

  7. Percentage of Participants With Pain Response

    Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in AS, or a ≥50% decrease from baseline mean AS without increase in the PPI score, maintained for 2 consecutive evaluations at least 3 weeks apart. Increases in pain during the first 12 weeks were ignored in determining pain response.

    Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)

  8. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of Health Related Quality of Life (HRQoL)

    FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P TOI combines physical well-being, functional well-being, and prostate-specific concerns sub-scales for a total possible score range of 0 to 104, where higher values represent better HRQoL.

    Time frame: Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)

  9. Change From Baseline in FACT-P:Total Score as a Measure of HRQoL

    FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL.

    Time frame: Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)

  10. Percentage of Participants With FACT-P Total Score Response

    FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL. Responder of FACT-P was defined as at least one occurrence of 7-point improvement from baseline in FACT-P total score during treatment period.

    Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)

  11. Time to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales

    The time to definitive deterioration (10% decrease in score from baseline) was assessed for the individual sub-scales (Physical Well-Being; Social/Family Well-Being; Emotional Well-Being; Functional Well-Being; Prostate-Specific Concerns). Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)

  12. Time to Definitive Deterioration of ECOG PS Score From Baseline

    The ECOG PS was used to evaluate participant's DP and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50 % of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG PS score from baseline was defined as a change from 0, 1 to ≥2, or from 2 to ≥3. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until death or study cut-off date (maximum duration: 48 months)

  13. Time to Definitive Weight Loss by 5% and 10% From Baseline

    Time to definitive weight loss was defined as the time to first occurrence of ≥5% or ≥10% decrease in body weight from baseline. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until death or study cut-off date (maximum duration: 48 months)

  14. Time to First Definitive Consumption of Narcotic Medication

    Concomitant medications used were recorded for all participants, and time of first definitive consumption of narcotic medication (if it occurred) was determined. This measure summarizes the time from baseline to first definitive consumption of narcotic medication. Analysis was performed by Kaplan-Meier method.

    Time frame: From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)

  15. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period. On-treatment period: The time from the first dose of treatment to 30 days after the last dose of treatment (either Cabazitaxel or Prednisone). A serious adverse event: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03 (Grade 3 \[severe\] and Grade 4 \[life-threatening\]) was used in this study to grade clinical AEs.

    Time frame: From first administration of study treatment until 30 days after the last administration of study treatment (Maximum duration: 48 months)

  16. Plasma Clearance (CL) for Cabazitaxel

    Blood samples for pharmacokinetic (PK) analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.

    Time frame: Day 1 of Cycle 1: 5 minutes before the end of infusion (EOI), 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI

  17. Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel

    Blood samples for PK analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.

    Time frame: Day 1 of Cycle 1: 5 minutes before the EOI, 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI

07

Results

Posted Oct 11, 2016

Participant flow

The study was conducted at 172 centers in 22 countries. A total of 1463 participants were screened between 19 April 2011 and 18 November 2013. Out of 1463 participants, 1200 participants were enrolled in this study and 263 were not eligible to join the study.

Participant flow — Overall Study
MilestoneCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Started598602
Treated587588
Completed586595
Not completed127
Withdrew: Lost to follow-up127

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earlier of the last date the participant was known to be alive or the study cut-off date. The cut-off date for the final analysis of OS was the date when the 988th death had been observed. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Median · months
Overall Survival (OS)
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Overall Survival (OS)13.4 (12.19 to 14.88)14.5 (13.47 to 15.28)
Statistical analysis
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.024Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.024Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
SecondaryProgression Free Survival (PFS)

PFS was evaluated from date of randomization to date of first documentation of any of the events: 1) Radiological tumor progression: as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target lesions, 2) Prostate Specific Antigen (PSA) progression: ≥25% increase over baseline/nadir value if baseline PSA ≥10 ng/mL; or 25% increase above the baseline level if baseline PSA \>0 ng/mL \& \<10 ng/mL; or post-baseline value of \>=2 ng/mL, if baseline PSA=0 ng/mL, 3) Pain progression: increase of ≥1 point in median Present Pain Intensity (PPI) from nadir or ≥25% increase in mean analgesic score (AS) from baseline score or requirement of local palliative radiotherapy, 4) Death. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline up to tumor progression, PSA progression, pain progression, death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Progression Free Survival (PFS)2.9 (2.79 to 3.45)3.5 (3.12 to 3.94)
Statistical analysis
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.099 · 95% CI 0.974 to 1.24Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
SecondaryTime to Tumor Progression

Time to Tumor progression was defined as the first occurrence of radiological tumor progression according to RECIST 1.1. Radiological tumor progression was defined at least a 20% increase in sum of diameters of target lesions (sum must also demonstrate an absolute increase of ≥5 mm) taking as reference the smallest sum while on study, appearance of one or more new lesions, or unequivocal progression of existing non target-lesions. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Median · months
Time to Tumor Progression
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Tumor Progression9.0 (8.38 to 9.79)9.3 (8.61 to 9.92)
Statistical analysis
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.096 · 95% CI 0.902 to 1.331Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
SecondaryPercentage of Participants With Overall Objective Tumor Response

Overall objective tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1 criteria, as assessed by the investigator. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Objective Tumor Response
percentage of participantsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With Overall Objective Tumor Response18.5 (13.8 to 23.1)23.4 (18.2 to 28.6)
SecondaryTime to PSA Progression

Time to PSA progression was time interval between randomization \& first occurrence of PSA progression. PSA progression defined as: 1) PSA responders (\>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over nadir value, confirmed by second PSA ≥3 weeks later; 2) PSA non-responders (did not achieve \>50% decline from baseline PSA ≥10 ng/mL): increase of ≥25% (≥2 ng/mL) over baseline value, confirmed by second PSA ≥3 weeks later; 3) In participants not eligible for PSA response (baseline PSA \<10 ng/mL): (a) participants with baseline PSA \>0 ng/mL \& \<10 ng/mL: increase in PSA by 25% (≥2 ng/mL) above baseline level, confirmed by second PSA value ≥3 weeks apart; (b) participants with baseline value=0 ng/mL: post-baseline PSA value ≥2 ng/mL. Note (for 1-3): Rise in PSA in first 12 weeks was progression only if met definition above and was associated with other sign of DP or if it continued beyond 12 weeks. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Median · months
Time to PSA Progression
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to PSA Progression5.7 (4.96 to 6.47)6.8 (6.11 to 7.46)
Statistical analysis
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.195 · 95% CI 1.025 to 1.393Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
SecondaryPercentage of Participants With PSA Response

PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.

Time frame:
From baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PSA Response
percentage of participantsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With PSA Response29.5 (25.6 to 33.3)42.9 (38.8 to 47.1)
SecondaryTime to Pain Progression

Pain Progression was defined as an increase of ≥1 point in the median PPI from its nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean AS compared with the baseline score confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. AS was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Reported as:
Median · months
Time to Pain Progression
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Pain Progression6.2 (5.22 to 7.39)6.4 (5.55 to 7.26)
Statistical analysis
  • Cabazitaxel 20 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.046 · 95% CI 0.874 to 1.251Cabazitaxel 20 mg/m\^2 vs Cabazitaxel 25 mg/m\^2
SecondaryPercentage of Participants With Pain Response

Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in AS, or a ≥50% decrease from baseline mean AS without increase in the PPI score, maintained for 2 consecutive evaluations at least 3 weeks apart. Increases in pain during the first 12 weeks were ignored in determining pain response.

Time frame:
From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Response
percentage of participantsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With Pain Response34.7 (28.8 to 40.6)37.3 (31.7 to 42.9)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of Health Related Quality of Life (HRQoL)

FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P TOI combines physical well-being, functional well-being, and prostate-specific concerns sub-scales for a total possible score range of 0 to 104, where higher values represent better HRQoL.

Time frame:
Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of Health Related Quality of Life (HRQoL)
units on a scaleCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Change from baseline at cycle 1 (n =521, 494)4.69 (2.95 to 6.44)5.08 (3.32 to 6.84)
Change from baseline at cycle 2 (n = 500, 494)4.4 (2.67 to 6.14)5.55 (3.81 to 7.3)
Change from baseline at cycle 3 (n =456, 451)3.75 (2 to 5.5)5.46 (3.7 to 7.23)
Change from baseline at cycle 4 (n =420, 415)2.57 (0.8 to 4.33)3.82 (2.04 to 5.6)
Change from baseline at cycle 5 (n =339, 361)1.78 (-0.03 to 3.59)3.06 (1.26 to 4.87)
Change from baseline at cycle 6 (n =275, 318)2.57 (0.72 to 4.43)2.03 (0.2 to 3.86)
Change from baseline at cycle 7 (n =225, 262)2.51 (0.6 to 4.42)2.73 (0.85 to 4.6)
Change from baseline at cycle 8 (n =196, 227)1.44 (-0.5 to 3.39)2.08 (0.16 to 3.99)
Change from baseline at cycle 9 (n =165, 172)0.94 (-1.06 to 2.94)1.46 (-0.55 to 3.46)
Change from baseline at cycle 10 (n =137, 141)0.02 (-2.05 to 2.1)1.31 (-0.76 to 3.39)
Change from baseline at Follow-up 1 (n =136, 152)-2.27 (-4.35 to -0.19)-1.16 (-3.21 to 0.88)
SecondaryChange From Baseline in FACT-P:Total Score as a Measure of HRQoL

FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL.

Time frame:
Baseline, Day 1 of each Cycle 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (each cycle 21-day); post-treatment follow up 1 (up to 12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline in FACT-P:Total Score as a Measure of HRQoL
units on a scaleCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Change from baseline at cycle 1 (n =521, 495)5.6 (3.43 to 7.78)5.75 (3.55 to 7.95)
Change from baseline at cycle 2 (n = 502, 492)5.39 (3.23 to 7.55)6.23 (4.05 to 8.42)
Change from baseline at cycle 3 (n = 459, 452)4.39 (2.21 to 6.57)6.09 (3.89 to 8.3)
Change from baseline at cycle 4 (n = 421, 415)2.94 (0.73 to 5.14)4.2 (1.98 to 6.42)
Change from baseline at cycle 5 (n = 339, 365)1.79 (-0.46 to 4.04)3.33 (1.08 to 5.59)
Change from baseline at cycle 6 (n = 275, 320)2.57 (0.26 to 4.88)2.35 (0.06 to 4.64)
Change from baseline at cycle 7 (n = 229, 267)2.62 (0.25 to 4.99)2.72 (0.38 to 5.06)
Change from baseline at cycle 8 (n = 196, 226)1.35 (-1.08 to 3.78)1.98 (-0.42 to 4.37)
Change from baseline at cycle 9 (n = 164, 172)1.1 (-1.4 to 3.6)1 (-1.5 to 3.51)
Change from baseline at cycle 10 (n = 137, 141)0.02 (-2.57 to 2.61)1.33 (-1.26 to 3.93)
Change from baseline at Follow-up 1 (n = 137, 153)-3.1 (-5.69 to -0.51)-2.09 (-4.65 to 0.46)
SecondaryPercentage of Participants With FACT-P Total Score Response

FACT-P is a 39-item participant questionnaire that measures the concerns of participants with prostate cancer. It consists of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P Total Score sums all 5 sub-scales to give a score in the range of 0 to 156, where higher values represent better HRQoL. Responder of FACT-P was defined as at least one occurrence of 7-point improvement from baseline in FACT-P total score during treatment period.

Time frame:
From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Reported as:
Number · percentage of participants
Percentage of Participants With FACT-P Total Score Response
percentage of participantsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With FACT-P Total Score Response57.2 (53.0 to 61.4)59.4 (55.2 to 63.6)
SecondaryTime to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales

The time to definitive deterioration (10% decrease in score from baseline) was assessed for the individual sub-scales (Physical Well-Being; Social/Family Well-Being; Emotional Well-Being; Functional Well-Being; Prostate-Specific Concerns). Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Reported as:
Median · months
Time to Definitive Deterioration of Score by 10% From Baseline on FACT-P Sub-Scales
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Physical well-being6.6 (5.85 to 7.82)8.3 (7.16 to 8.74)
Social/family well-being10.8 (9.26 to 13.37)12.4 (8.97 to 13.83)
Emotional well-being9.7 (7.36 to 11.30)9.9 (8.54 to 12.52)
Functional well-being6.6 (5.55 to 7.43)6.7 (6.01 to 8.34)
Prostate specific concern8.7 (7.62 to 9.66)9.7 (8.77 to 10.87)
SecondaryTime to Definitive Deterioration of ECOG PS Score From Baseline

The ECOG PS was used to evaluate participant's DP and the effect of the disease on the participant's activities of daily living. It ranges on the scale from 0-5 (0= normal activity; 1= symptoms but ambulatory; 2= in bed for \< 50 % of the time; 3= in bed for \> 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG PS score from baseline was defined as a change from 0, 1 to ≥2, or from 2 to ≥3. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until death or study cut-off date (maximum duration: 48 months)
Reported as:
Median · months
Time to Definitive Deterioration of ECOG PS Score From Baseline
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Definitive Deterioration of ECOG PS Score From Baseline14.9 (11.43 to 23.59)14.1 (12.22 to 20.17)
SecondaryTime to Definitive Weight Loss by 5% and 10% From Baseline

Time to definitive weight loss was defined as the time to first occurrence of ≥5% or ≥10% decrease in body weight from baseline. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until death or study cut-off date (maximum duration: 48 months)
Reported as:
Median · months
Time to Definitive Weight Loss by 5% and 10% From Baseline
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Weight Loss by 5%10.6 (9.26 to 13.17)11.1 (10.12 to 12.42)
Weight Loss by 10%NA (12.65 to NA)20.3 (14.23 to NA)
SecondaryTime to First Definitive Consumption of Narcotic Medication

Concomitant medications used were recorded for all participants, and time of first definitive consumption of narcotic medication (if it occurred) was determined. This measure summarizes the time from baseline to first definitive consumption of narcotic medication. Analysis was performed by Kaplan-Meier method.

Time frame:
From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)
Reported as:
Median · months
Time to First Definitive Consumption of Narcotic Medication
monthsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to First Definitive Consumption of Narcotic Medication2.2 (0.99 to 3.65)0.8 (0.30 to 2.20)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during on-treatment period. On-treatment period: The time from the first dose of treatment to 30 days after the last dose of treatment (either Cabazitaxel or Prednisone). A serious adverse event: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) version 4.03 (Grade 3 \[severe\] and Grade 4 \[life-threatening\]) was used in this study to grade clinical AEs.

Time frame:
From first administration of study treatment until 30 days after the last administration of study treatment (Maximum duration: 48 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Any Grade TEAE91.293.9
Any Grade 3-4 TEAE39.754.5
Grade 3-4 TEAE excluding laboratory TEAE35.748.1
Grade 3-4 TEAE excluding DP TEAEs39.053.9
Grade 3-4 TEAE excluding laboratory and DP TEAEs35.047.4
Any Serious TEAE30.543.2
Any TEAE leading to permanent discontinuation16.419.5
SecondaryPlasma Clearance (CL) for Cabazitaxel

Blood samples for pharmacokinetic (PK) analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.

Time frame:
Day 1 of Cycle 1: 5 minutes before the end of infusion (EOI), 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI
Reported as:
Mean · Litre/hour
Plasma Clearance (CL) for Cabazitaxel
Litre/hourCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Plasma Clearance (CL) for Cabazitaxel44.832 ± 15.07549.662 ± 17.613
SecondaryPlasma Steady State Volume of Distribution (Vss) for Cabazitaxel

Blood samples for PK analysis were obtained from a subset of the study participants (approximately 150 participants/group, by protocol) according to a sparse sampling strategy.

Time frame:
Day 1 of Cycle 1: 5 minutes before the EOI, 15 minutes, 1 to 4 hour, 6 to 24 hours, 48 to 168 hour after EOI
Reported as:
Mean · litre
Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel
litreCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Plasma Steady State Volume of Distribution (Vss) for Cabazitaxel7381.46 ± 4488.727040.10 ± 5133.12

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to the final visit (48 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabazitaxel 20 mg/m^2—177/580 (30.5%)450/580 (77.6%)
Cabazitaxel 25 mg/m^2—257/595 (43.2%)507/595 (85.2%)
Most frequent serious events
Showing 10 of 217
Most frequent serious events
EventCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders10/58048/595
NeutropeniaBlood and lymphatic system disorders3/58027/595
HaematuriaRenal and urinary disorders13/58021/595
Neutropenic infectionInfections and infestations8/58017/595
Urinary tract infectionInfections and infestations9/58017/595
Neutropenic sepsisInfections and infestations7/58014/595
AnaemiaBlood and lymphatic system disorders13/58012/595
DiarrhoeaGastrointestinal disorders5/58013/595
Disease progressionGeneral disorders8/58013/595
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/5808/595
Most frequent other events
Showing 10 of 27
Most frequent other events
EventCabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
DiarrhoeaGastrointestinal disorders175/580231/595
NauseaGastrointestinal disorders140/580188/595
FatigueGeneral disorders142/580156/595
AstheniaGeneral disorders88/580114/595
Decreased appetiteMetabolism and nutrition disorders74/580108/595
HaematuriaRenal and urinary disorders73/580108/595
ConstipationGastrointestinal disorders102/580107/595
VomitingGastrointestinal disorders78/580105/595
Back painMusculoskeletal and connective tissue disorders63/58078/595
DysgeusiaNervous system disorders41/58063/595

Baseline characteristics

Age, Customized
Age, Customized(participants)Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2Total
<65 years182180362
65 to 74 years296295591
≥75 years120127247
Sex: Female, Male
Sex: Female, Male(Participants)Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2Total
Female000
Male5986021200
08

Study locations

172 sites
  • Investigational Site Number 840002
    Muscle Shoals, Alabama 35661, United States
  • Investigational Site Number 840004
    Hot Springs, Arkansas 71913, United States
  • Investigational Site Number 840008
    Anaheim, California 92801, United States
  • Investigational Site Number 840010
    La Jolla, California 92093, United States
  • Investigational Site Number 840001
    San Bernardino, California 92404, United States
  • Investigational Site Number 840021
    Stamford, Connecticut 06902, United States
  • Investigational Site Number 840023
    Jacksonville, Florida 32256, United States
  • Investigational Site Number 840013
    Lakeland, Florida 33805, United States
  • Investigational Site Number 840003
    Port St. Lucie, Florida 34952, United States
  • Investigational Site Number 840007
    New Orleans, Louisiana 70112, United States
  • Investigational Site Number 840014
    Baltimore, Maryland 21231, United States
  • Investigational Site Number 840005
    Rockville, Maryland 20850, United States
  • Investigational Site Number 840017
    St Louis Park, Minnesota 55416, United States
  • Investigational Site Number 840011
    Jackson, Mississippi 39202, United States
  • Investigational Site Number 840016
    Lincoln, Nebraska 68506, United States
  • Investigational Site Number 840015
    East Orange, New Jersey 07018, United States
  • Investigational Site Number 840024
    Raleigh, North Carolina 27607, United States
  • Investigational Site Number 840020
    Akron, Ohio 44302, United States
  • Investigational Site Number 840006
    Pawtucket, Rhode Island 02860, United States
  • Investigational Site Number 840025
    Chattanooga, Tennessee 37421, United States
  • Investigational Site Number 840012
    Corpus Christi, Texas 78405, United States
  • Investigational Site Number 032002
    Buenos Aires, C1120AAT, Argentina
  • Investigational Site Number 032001
    Rosario, 2000, Argentina
  • Investigational Site Number 032003
    Salta, A4406CLA, Argentina
  • Investigational Site Number 032004
    Santa Fe, 3000, Argentina
  • Investigational Site Number 036014
    Adelaide, 5000, Australia
  • Investigational Site Number 036013
    Bankstown, 2200, Australia
  • Investigational Site Number 036010
    Box Hill, 3128, Australia
  • Investigational Site Number 036012
    Camperdown, 2050, Australia
  • Investigational Site Number 036008
    Coffs Harbour, 2450, Australia
  • Investigational Site Number 036001
    Concord, 2137, Australia
  • Investigational Site Number 036015
    Elizabeth Vale, 5112, Australia
  • Investigational Site Number 036009
    Fitzroy, 3065, Australia
  • Investigational Site Number 036007
    Garran, 2605, Australia
  • Investigational Site Number 036005
    Heidelberg West, 3081, Australia
  • Investigational Site Number 036002
    Malvern, 3144, Australia
  • Investigational Site Number 036006
    South Brisbane, 4101, Australia
  • Investigational Site Number 036016
    Subiaco, 6008, Australia
  • Investigational Site Number 036003
    Wahroonga, 2076, Australia
  • Investigational Site Number 036004
    Wodonga, 3690, Australia
  • Investigational Site Number 056007
    Antwerpen, B-2020, Belgium
  • Investigational Site Number 056008
    Brussel, 1090, Belgium
  • Investigational Site Number 056001
    Bruxelles, 1000, Belgium
  • Investigational Site Number 056002
    Bruxelles, 1200, Belgium
  • Investigational Site Number 056009
    Charleroi, B-6000, Belgium
  • Investigational Site Number 056003
    Gent, 9000, Belgium
  • Investigational Site Number 056012
    Godinne, B-5530, Belgium
  • Investigational Site Number 056016
    Haine-Saint-Paul, 7100, Belgium
  • Investigational Site Number 056005
    Hasselt, B-3500, Belgium
  • Investigational Site Number 056010
    Libramont, 6800, Belgium
  • Investigational Site Number 056013
    Liège, 4000, Belgium
  • Investigational Site Number 056011
    Ottignies, 1340, Belgium
  • Investigational Site Number 056004
    Roeselare, 8800, Belgium
  • Investigational Site Number 056006
    Turnhout, B-2300, Belgium
  • Investigational Site Number 076016
    Fortaleza, Brazil
  • Investigational Site Number 076012
    Ijui, 98700 000, Brazil
  • Investigational Site Number 076015
    Mogi Das Cruzes, 08730-500, Brazil
  • Investigational Site Number 076014
    Porto Alegre, 90110-270, Brazil
  • Investigational Site Number 076010
    Rio De Janeiro, 22793-080, Brazil
  • Investigational Site Number 076007
    Salvador, 41256-900, Brazil
  • Investigational Site Number 076003
    Sao Jose Do Rio Preto, 15090-000, Brazil
  • Investigational Site Number 076009
    Sao Paulo, 01221-020, Brazil
  • Investigational Site Number 076001
    Sao Paulo, 01308050, Brazil
  • Investigational Site Number 076013
    Sao Paulo, 01321-001, Brazil
  • Investigational Site Number 076008
    Sao Paulo, 01509-900, Brazil
  • Investigational Site Number 076002
    Sao Paulo, 03102-002, Brazil
  • Investigational Site Number 124002
    Greenfield Park, J4V 2H1, Canada
  • Investigational Site Number 124001
    Oshawa, L1G 2B9, Canada
  • Investigational Site Number 124003
    Ottawa, K1H 8L6, Canada
  • Investigational Site Number 124005
    Owen Sound, N4K 2J1, Canada
  • Investigational Site Number 152005
    Santiago, 751-0009, Chile
  • Investigational Site Number 152004
    Santiago, 7510032, Chile
  • Investigational Site Number 152002
    Santiago, 8380456, Chile
  • Investigational Site Number 152001
    Viña Del Mar, 2540364, Chile
  • Investigational Site Number 250005
    Avignon Cedex 9, 84918, France
  • Investigational Site Number 250008
    Hyeres, 83400, France
  • Investigational Site Number 250001
    La Roche Sur Yon, 85925, France
  • Investigational Site Number 250002
    Nantes Cedex 2, 44202, France
  • Investigational Site Number 250004
    Nimes, 30029, France
  • Investigational Site Number 250010
    Paris, 75014, France
  • Investigational Site Number 250009
    Reims Cedex, 51056, France
  • Investigational Site Number 250007
    Reims, 51100, France
  • Investigational Site Number 250006
    Saint Brieuc Cedex, 22015, France
  • Investigational Site Number 250011
    Toulouse Cedex 03, 31076, France
  • Investigational Site Number 250003
    Toulouse Cedex 09, 31052, France
  • Investigational Site Number 276003
    Aachen, 52074, Germany
  • Investigational Site Number 276007
    Dresden, 01307, Germany
  • Investigational Site Number 276004
    Düsseldorf, 40225, Germany
  • Investigational Site Number 276001
    Erlangen, 91054, Germany
  • Investigational Site Number 276011
    Hamburg, 20246, Germany
  • Investigational Site Number 276005
    Hamburg, 22399, Germany
  • Investigational Site Number 276010
    Homburg, 66421, Germany
  • Investigational Site Number 276006
    München, 81675, Germany
  • Investigational Site Number 276012
    Nürtingen, 72622, Germany
  • Investigational Site Number 276008
    Tübingen, 72076, Germany
  • Investigational Site Number 276002
    Wuppertal, 42103, Germany
  • Investigational Site Number 348001
    Budapest, 1122, Hungary
  • Investigational Site Number 348005
    Budapest, 1134, Hungary
  • Investigational Site Number 348004
    Budapest, 1145, Hungary
  • Investigational Site Number 348006
    Miskolc, 3526, Hungary

Showing the first 100 of 172 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Meisel A, de Wit R, Oudard S, Sartor O, Stenner-Liewen F, Shun Z, Foster M, Ozatilgan A, Eisenberger M, de Bono JS. Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2022 Jun 1;14:17588359221100022. doi: 10.1177/17588359221100022. eCollection 2022. PubMed 35677318 ↗
  • Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open. 2021 Apr;6(2):100089. doi: 10.1016/j.esmoop.2021.100089. Epub 2021 Mar 16. PubMed 33740734 ↗
  • Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Mace S, de Bono JS. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28. PubMed 29500065 ↗
  • Eisenberger M, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15. PubMed 28809610 ↗
  • Winquist E, Rodrigues G. Open clinical uro-oncology trials in Canada. Can J Urol. 2012 Dec;19(6):6587-91. No abstract available. PubMed 23228299 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2011
First posted
Mar 4, 2011
Start
Apr 2011
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Oct 11, 2016
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01308580
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2011
Start date
Apr 2011
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Oct 11, 2016
Last update
Apr 17, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabazitaxel · Prednisone

Start the discussion